logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

The pharmaceutical sector surged, with Chinese medicine stocks hitting their daily limit.

date
18/09/2025
In the medical business sector, there was a sharp rise, with China Pharmaceuticals hitting the daily limit, and shares of Luye Pharma Group, Shu Yumingmin, Kaikai Industrial, Laobaixing, and Yaeyigou following suit.
Latest
1 m ago
Stocks on the Hong Kong market saw unusual fluctuations, with Chinese brokerage stocks mostly dropping. The Fed's interest rate cut was in line with expectations, and institutions predict loose trading or marginal adjustments.
2 m ago
CICC published a report stating that, since September, domestic institutions' proportion of holdings through the Stock Connect program has remained stable, while foreign institutions' holdings in Hong Kong healthcare stocks have slightly decreased since the middle of the year. This week, domestic institutions increased their holdings in leading and innovative pharmaceutical companies, while foreign institutions increased their holdings in high cost-effective CXO companies. They reduced their holdings in innovative targets that domestic institutions were adding to. After a general rise in the innovative pharmaceutical sector, it is recommended to gradually enter the market during a decline and focus on the following specific directions: Three Stone Pharmaceuticals and Deqi Pharmaceuticals have rich short-term catalysts and their valuations still do not reflect the value of their core products. SinocellTech, Hutchison Pharma, and Legend Biotech are significantly undervalued with clear long-term growth prospects. In the CXO sector, leading downstream companies, such as Pharmaron, benefit from a strong business environment and marginally improved financing conditions.
2 m ago
CICC International: It is recommended to gradually layout in the innovative pharmaceutical sector during the pullback.
3 m ago
(LLY.US) 1028 Daiwa: Lilly (LLY.US) oral weight loss drug clinical trial data shining, maintains target price of $1028.
3 m ago
Changying Precision's trading volume has reached 10 billion yuan, and it is currently up more than 8%.
See all latestmore
logo
Contact US
qr
+852 - 60190728
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.